Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor

Table 2 MDA and NO levels in gastric tissues in each group

Group	n	MDA (nmol/g protein)	NO (μmol/g protein)
Sham	8	9.4 ± 4.47 (3.6-14.3)	35.67 ± 5.69 (30.21-46.63)
Indomethacin	8	28.48 ± 14.51 (7.1-45)a	27.20 ± 6.25 (20.0-38.78)
Famotidine 5 (F5)	8	6.21 ± 1.88 (3.4-9.5)	40.82 ± 9.42 (31.08-59.92)c
Famotidine20 (F20)	8	5.88 ± 1.60 (3.3-7.7)	51.22 ± 15.27 (34.24-77.50)c
Vardenafil 2 (V2)	8	15.87 ± 3.93 (11.6-23.8)e	31.01 ± 20.27 (21-55.15)e
Vardenafil 10 (V10)	8	10.97 ± 4.50 (5.4-19.9)gh	33.55 ± 9.29 (22.16-48.51)g

The values are presented as mean ± SD, (min-max).

^aP < 0.05 vs the other group;

^cP < 0.05 vs indomethacin group;

^eP < 0.05 vs famotidine groups (F5 and F20);

^gP < 0.05 vs group F20;

^hP < 0.01 vs group F20.